Related Experiment Video
Updated: May 2, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.5K
Sulfonylureas: a new look at old therapy
Peter M Thulé1, Guillermo Umpierrez
1Section Endocrinology and Metabolism, Atlanta VA Medical Center, Atlanta, GA, USA.
Current Diabetes Reports
|February 25, 2014
Summary
Sulfonylureas, the first oral antidiabetic agents, stimulate insulin release and offer glucose control benefits. However, their use in type 2 diabetes mellitus carries risks of hypoglycemia and weight gain, prompting ongoing safety debates.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Sulfonylureas represent the initial class of oral antidiabetic medications.
- They are crucial for managing glucose levels in type 2 diabetes mellitus (T2DM).
Purpose of the Study:
- To review the discovery, mechanisms of action, and clinical trial results of sulfonylureas.
- To provide practical insights into the advantages and disadvantages of sulfonylurea use in T2DM management.
Main Methods:
- Review of historical data on sulfonylurea discovery.
- Analysis of clinical trial outcomes regarding efficacy and safety.
- Examination of extrapancreatic effects and cardiovascular impact.
Main Results:
- Sulfonylureas enhance insulin secretion from pancreatic β-cells.
- Extrapancreatic effects include reduced hepatic insulin clearance and glucagon suppression.
- Clinical utility is debated due to risks of hypoglycemia and weight gain.
Conclusions:
- Sulfonylureas remain a significant therapeutic option for T2DM.
- A comprehensive understanding of their efficacy, side effects, and cardiovascular outcomes is essential for clinical practice.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:26Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
01:28Drug Therapy
449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
449
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K